Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407229 | 0.83 | DGAT1 (0.45) | NOTUMDGAT1ALDH1A1 | |
| SCHEMBL407419 | 0.81 | DGAT1 (0.54) | DGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL4486286 | 0.80 | SMN1; SMN2 (0.52) | DGAT1ALDH1A1 | |
| SCHEMBL408898 | 0.77 | DGAT1 (0.48) | DGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL408273 | 0.77 | DGAT1 (0.54) | DGAT1ALDH1A1L3MBTL1TDP1 | |
| SCHEMBL14319143 | 0.76 | DGAT1 (0.45) | DGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL408724 | 0.75 | DGAT1 (0.46) | NOTUMDGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL408204 | 0.75 | DGAT1 (0.41) | NOTUMDGAT1 | |
| SCHEMBL4293751 | 0.74 | ALDH1A1 (0.54) | DGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL408727 | 0.74 | DGAT1 (0.39) | DGAT1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | NOTUM 255/4885DGAT1 2/4885ALDH1A1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.